Management Team

Who we are:

Fosun Pharma USA Inc. established in 2017, is a subsidiary of a leading global healthcare group, Fosun Pharma (SSE: 600196) (SEHK:2196) and Fosun International Limited (SEHK: 656), a leading conglomerate and investment company.

Our management team has many years of experience in the pharma industry and bring a strong commitment to the growth of Fosun Pharma USA Inc.

Fosun Pharma USA

Lily Zou, Ph.D

CEO of Fosun Pharma USA, Inc.​

Lily is responsible for Commercial Operations, BD and Investment Activities in the US.

Lily brings extensive experience in BD/Investment, Strategy and Operations to Fosun pharma USA. Her prior experiences include management consultant at Bain & Co., BD/M&A, Strategic planning and R&D Management at Novartis/Sandoz, Wyeth, Millennium, Coley and ArQule. Lily has led the negotiation and execution of over 40 product BD/investment deals, including innovative and generic products.

Lily received a B.S. from Peking University, PhD in Molecular Biology from Cornell University and an MBA from MIT.

Lily Zou, Ph.D

CEO of Fosun Pharma USA Inc.
 

Fosun Pharma USA

Dr. Lijun Wu

CSO of Fosun Pharma USA, Inc. & Fosun Pharmaceutical Development Company

Dr. Lijun Wu is the Chief Scientific Officer of Fosun Pharma USA, Inc. and Fosun Pharmaceutical Development Company.  Prior to joining Fosun Pharma in 2018, she was an Entrepreneur-in-Residence at Atlas Venture and Senior Vice President of Preclinical and Early positions in the biotech and pharmaceutical industry including Vice President of Biology and Preclinical R&D at Concert Pharmaceuticals, Vice President of Discovery Research at Resolvyx Pharmaceuticals, Executive Director of Cardiovascular Research at the Novartis Institutes for BioMedical Research, and Director of Molecular and Cellular Pharmacology at Millennium Pharmaceuticals.

Dr. Wu is a seasoned executive with >20-years of experience in startup, established biotech, and large pharmaceutical companies.  She is an author of over 60 peer-reviewed publications an inventor on a number of patents, and the recipient of Massachusetts High Tech’s “Women to Watch” award.  She has been serving on the advisory council of IBBS/Johns Hopkins School of Medicine and is a member of JHU’s Society of Scholars.

Dr. Wu received her Ph.D. in Biochemistry, Molecular Biology and Cell Biology from Northwestern University and completed a postdoctoral fellowship at Johns Hopkins University School of Medicine.

Dr. Lijun Wu

CSO of Fosun Pharma USA Inc. & Fosun Pharmaceutical Development Company

Fosun Pharma USA

Weicheng Wu, Ph.D., RAC

VP, Regulatory Affairs

Weicheng has 17 years of experience in Regulatory Affairs. Weicheng’s experience includes medical writing at Allergan, and Regulatory Affairs positions with increased responsibilities at Wats on Pharmaceutical, Qualitest/Endo/Par, Jiangsu Hengrui Medicine, for US and EU filings.

Weicheng has a Ph.D. in Biochemistry & Molecular Biology and M.S. in Regulatory Science from University of Southern California.

Weicheng Wu, Ph.D., RAC

VP, Regulatory Affairs of
Fosun Pharma USA Inc.

Fosun Pharma USA

Grace Shen, R.Ph

VP of Sales & Marketing

Grace Shen, R.Ph is responsible for Sales and Marketing Strategy and management of Commercial Operations in the US. Grace has over 30 years industry experience including Sales & Marketing Strategy, Portfolio Management/Development, Product launch planning & market share growth of generics, 505b2, specialty drugs. She brings in-depth relationships with key industry customers and understanding of market segments trends including managed care.

Grace’s prior experience includes working at Teva, Sun Pharma USA, Jubilant as well as with various customers in different business segments (i.e. Hospital/Clinic, GPOs, wholesalers, Longterm Care, Mail-order, PBMs, retailers (chain, food, independent, mail order and others).

Grace has a B.S. from University of Houston School of Pharmacy.

Grace Shen, R.Ph

VP of Sales & Marketing of
Fosun Pharma USA Inc.

Fosun Pharma USA

Huong Nguyen, Esq.

VP, General Counsel

Huong Nguyen is currently Vice President, General Counsel, of Fosun Pharma USA Inc. She has spent the majority of her nearly two-decade law practice actively working in the pharmaceutical industry as both an in-house counsel and a private practitioner. Throughout this time she has partnered with a wide variety of cross-functional groups, and has directly counseled senior management and Boards of Directors in her areas of expertise.

Huong spent the early years of her legal career in private practice at two consecutive national (US) law firms as a commercial and IP litigator and IP counsel. Thereafter, she spent almost ten years at a specialty pharmaceutical company as in-house counsel, with increasing responsibilities through the years in litigation, IP, and employment matters. While in-house, Huong also spearheaded internal and government investigations that resulted in her appearing before the US Federal Trade Commission, US Department of Justice, and State Attorneys General in defense of the company. She left her first pharmaceutical company for private practice in order to expand her experience in M&A and BD and commercial transactions.

In 2019, Huong joined Fosun as General Counsel, with deep and wide-ranging experiences in litigation, IP, compliance, M&A, BD and commercial transactions, and employment. During the COVID-19 pandemic, Huong also assisted Fosun in the sales and distribution of medical supplies and devices, including PPE and Fosun’s own RT-PCR and Antibody Detection Kits.

Huong received her BA at the University of California, Los Angeles and her JD at the University of California, Hastings College of the Law.

Huong Nguyen, Esq.

VP, General Counsel of
Fosun Pharma USA Inc.

Fosun Pharma USA

Christopher Childs, MBA

 

Chris is responsible for BD&L activities in the US and has 25 years of pharmaceutical industry experience spanning business and scientific disciplines. 

Chris’ prior scientific experience includes positions of increasing responsibility at Organogenesis, Genetics Institute/Wyeth, and Novartis (NIBR).  His business and corporate development experience includes positions of increasing responsibility at Indevus Pharmaceuticals, Endo International, and Teva Pharmaceuticals and encompasses a wide range of transactions including:  in- and out-licensing, asset acquisitions and divestitures, and M&A in both the generics and branded pharmaceutical spaces.

Chris received his B.S. in Biology from the University of Massachusetts at Lowell, his A.L.M with a concentration in molecular biology and original thesis work in RNA interference from Harvard University, and his M.B.A. from Boston University.

Christopher Childs, MBA

Fosun Pharma USA Inc.